Chemical Structure (Elepsia 01)
Elepsia Xr 1500 Mg Tablet, Extended Release
Product Images NDC 80705-101
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Elepsia Xr 1500 Mg (NDC 80705-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Tripoint Therapeutics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Elepsia 02)
This is a chart showing the percentage of patients in a clinical trial who had a certain response to different doses of immediate-release Levetiracetam, compared to a placebo group. The percentages range from 0-45%. The text also includes the number of patients in each group (N=95 and N=101) and the doses of Levetiracetam administered (1,000 mg/day and 3,000 mg/day).*
Figure 2 (Elepsia 03)
This appears to be a graph showing the percent of patients for three different treatment groups (placebo, immediate-release Levetiracetam 1,000mg/day, and immediate-release Levetiracetam 2,000mg/day). The percentages range from 0-45%. However, without additional context, it is not possible to determine what the graph is specifically measuring or evaluating.*
Figure 3 (Elepsia 04)
This appears to be a chart showing the percentage of patients in various categories, ranging from 0% to 45%. There are two treatment groups being compared: placebo (N=104) and immediate-release Levetiracetam 3,000 mg/day (N=180). However, without context or additional information, it is difficult to assess the purpose or meaning of the chart.*
Figure 4 (Elepsia 05)
This is a chart displaying the percentage of patients in a study. The percentages range from 0% to 45%, with the majority of the data falling between 20% and 45%. The study involves a placebo group, represented as "Placebo (N=97)", and a group taking a medication called "Immediate-release Levetiracetam (!01)". There is also a value of 19.6% shown on the chart that is not clearly attributed to either group.*
Principal Display Panel (1000 mg Tablet Bottle Label)
ELEPSIA XR is a medication that is usually taken once daily. Each tablet contains 1000 mg of Levetiracetam USP. Instructions suggest that it should be swallowed whole and not chewed, crushed, broken, or split. The package insert provides complete dosage recommendations for use. It should be stored at a temperature between 20°C to 25°C (68°F to 77°F), and can be kept between 15°C and 30°C (59°F and 86°F) for a short while, while dispensing it, in a tight, light-resistant container with a child-resistant closure. Pharmacists should provide the medication guide to each patient. Manufactured by Sun Pharmaceutical Industries Ltd., it is meant for Tripoint Therapeutics, LLC. Noc 80705-100-30 is its identification number.*
Principal Display Panel (1500 mg Tablet Bottle Label)
This text provides instructions and information regarding the usual dosage, storage, and dispensing of ELEPSIA XR tablets. The tablets contain 1500 mg of Levetiracetam USP, an anticonvulsant medication used for treating epilepsy. The tablets should be swallowed whole and not be chewed, crushed, split or broken. The medication guide is available at the Tripoint Therapeutics website. The tablets should be stored at room temperature between 20°C to 25°C and dispensed in a tight, light-resistant container with a child-resistant closure. Pharmacists should dispense the medication along with the medication guide.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
